Replies to post #145677 on Biotech Values

[DewDiligence]

Do you think payers will favor reimbursing gammagard vs. others in that scenario? I was also wondering if the results are positive but treatment effect is marginal if insurers will try to make patients use other treatments (like aricept and namenda).

Good questions. My guesses are: 1) no; 2) yes.